中性原胺海格多恩 (NPH) 胰岛素减轻了糖尿病大鼠的记忆障碍
Marcelo T Andrade1,2, Camila B Gomes1, Débora O Fernandes1
1Exercise Physiology Laboratory, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Av. Antônio Carlos, Belo Horizonte, MG, 662731270-901, Brazil.
Diabetology & metabolic syndrome
|July 11, 2025
概括
中性原胺海格多恩 (NPH) 胰岛素在患有1型糖尿病 (T1D) 的老鼠中对记忆丧失进行了部分保护. 虽然没有完全恢复功能,但NPH胰岛素治疗延迟了与糖尿病相关的认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型糖尿病 (T1D) 与认知能力下降有关,影响患者的生活质量.
- 中性原胺海格多恩 (NPH) 胰岛素对糖尿病相关认知障碍的神经保护作用尚不清楚.
研究的目的:
- 为了研究NPH胰岛素在减轻小鼠的空间,短期和长期记忆缺陷中的疗效,在链毒素诱导的T1D (T1DSTZ) 鼠.
- 评估NPH胰岛素治疗30天内认知缺陷的进展情况.
主要方法:
- 成年雄性Wistar大鼠使用链毒素 (STZ) 诱导T1D,并随机分配到糖尿病或非糖尿病组.
- 糖尿病老鼠每天接受两次NPH胰岛素注射.
- 在10,20和30天使用新物体识别和空间物体识别任务来评估认知功能.
主要成果:
- 在T1DSTZ大鼠中,NPH胰岛素治疗显著延迟了空间,短期和长期记忆缺陷的进展.
- 虽然记忆功能没有完全恢复,但胰岛素治疗表明部分神经保护.
- 即使在接受治疗后,T1DSTZ大鼠仍然表现出记忆障碍,这表明了糖尿病相关认知衰退的复杂性.
结论:
- 在T1DSTZ大鼠中,NPH胰岛素提供了对认知衰退的部分神经保护.
- 早期和一致的糖尿病管理对于保持认知功能至关重要.
- 需要进一步的研究来优化胰岛素治疗以预防和减少与糖尿病相关的认知障碍.
更多相关视频
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


